Inhibition of AT1R signaling with AT1R blockers (ARBs) such as telmisartan and losartan to reduce the harmful effects of Ang II/AT1R axis while enhancing the ACE2/Ang (1–7) protective axis, has also been proposed as a strategy to counteract its excessive stimulation in COVID-19, with resulting microvascular inflammation, coagulation and fibrosis. Here, ACE2 is linked to COVID-19.